168 related articles for article (PubMed ID: 9855502)
1. Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer's disease.
Lovell MA; Xie C; Markesbery WR
Neurology; 1998 Dec; 51(6):1562-6. PubMed ID: 9855502
[TBL] [Abstract][Full Text] [Related]
2. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease.
Markesbery WR; Lovell MA
Neurobiol Aging; 1998; 19(1):33-6. PubMed ID: 9562500
[TBL] [Abstract][Full Text] [Related]
3. Increased brain levels of 4-hydroxy-2-nonenal glutathione conjugates in severe Alzheimer's disease.
Völkel W; Sicilia T; Pähler A; Gsell W; Tatschner T; Jellinger K; Leblhuber F; Riederer P; Lutz WK; Götz ME
Neurochem Int; 2006 Jun; 48(8):679-86. PubMed ID: 16483694
[TBL] [Abstract][Full Text] [Related]
4. Glutathione transferase protects neuronal cultures against four hydroxynonenal toxicity.
Xie C; Lovell MA; Markesbery WR
Free Radic Biol Med; 1998 Nov; 25(8):979-88. PubMed ID: 9840744
[TBL] [Abstract][Full Text] [Related]
5. Oxidatively modified GST and MRP1 in Alzheimer's disease brain: implications for accumulation of reactive lipid peroxidation products.
Sultana R; Butterfield DA
Neurochem Res; 2004 Dec; 29(12):2215-20. PubMed ID: 15672542
[TBL] [Abstract][Full Text] [Related]
6. Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: possible relation to oxidative stress.
Deibel MA; Ehmann WD; Markesbery WR
J Neurol Sci; 1996 Nov; 143(1-2):137-42. PubMed ID: 8981312
[TBL] [Abstract][Full Text] [Related]
7. Nerve growth factor in Alzheimer's disease: increased levels throughout the brain coupled with declines in nucleus basalis.
Scott SA; Mufson EJ; Weingartner JA; Skau KA; Crutcher KA
J Neurosci; 1995 Sep; 15(9):6213-21. PubMed ID: 7666203
[TBL] [Abstract][Full Text] [Related]
8. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease.
Lovell MA; Ehmann WD; Butler SM; Markesbery WR
Neurology; 1995 Aug; 45(8):1594-601. PubMed ID: 7644059
[TBL] [Abstract][Full Text] [Related]
9. The expression of key oxidative stress-handling genes in different brain regions in Alzheimer's disease.
Aksenov MY; Tucker HM; Nair P; Aksenova MV; Butterfield DA; Estus S; Markesbery WR
J Mol Neurosci; 1998 Oct; 11(2):151-64. PubMed ID: 10096042
[TBL] [Abstract][Full Text] [Related]
10. Potential role of acrolein in neurodegeneration and in Alzheimer's disease.
Dang TN; Arseneault M; Murthy V; Ramassamy C
Curr Mol Pharmacol; 2010 Jun; 3(2):66-78. PubMed ID: 20302565
[TBL] [Abstract][Full Text] [Related]
11. Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease.
Lovell MA; Ehmann WD; Mattson MP; Markesbery WR
Neurobiol Aging; 1997; 18(5):457-61. PubMed ID: 9390770
[TBL] [Abstract][Full Text] [Related]
12. Association of 1H-MR spectroscopy and cerebrospinal fluid biomarkers in Alzheimer's disease: diverging behavior at three different brain regions.
Bittner DM; Heinze HJ; Kaufmann J
J Alzheimers Dis; 2013; 36(1):155-63. PubMed ID: 23579327
[TBL] [Abstract][Full Text] [Related]
13. Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures.
Lovell MA; Xie C; Markesbery WR
Neurobiol Aging; 2001; 22(2):187-94. PubMed ID: 11182468
[TBL] [Abstract][Full Text] [Related]
14. Unaltered brain levels of 1,N2-propanodeoxyguanosine adducts of trans-4-hydroxy-2-nonenal in Alzheimer's disease.
Götz ME; Wacker M; Luckhaus C; Wanek P; Tatschner T; Jellinger K; Leblhuber F; Ransmayr G; Riederer P; Eder E
Neurosci Lett; 2002 May; 324(1):49-52. PubMed ID: 11983292
[TBL] [Abstract][Full Text] [Related]
15. Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment.
Butterfield DA; Reed T; Perluigi M; De Marco C; Coccia R; Cini C; Sultana R
Neurosci Lett; 2006 Apr; 397(3):170-3. PubMed ID: 16413966
[TBL] [Abstract][Full Text] [Related]
16. Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer's disease.
Williams TI; Lynn BC; Markesbery WR; Lovell MA
Neurobiol Aging; 2006 Aug; 27(8):1094-9. PubMed ID: 15993986
[TBL] [Abstract][Full Text] [Related]
17. Amino acids, glutathione, and glutathione transferase activity in the brains of patients with Alzheimer's disease.
Perry TL; Yong VW; Bergeron C; Hansen S; Jones K
Ann Neurol; 1987 Apr; 21(4):331-6. PubMed ID: 3579218
[TBL] [Abstract][Full Text] [Related]
18. Impaired proteasome function in Alzheimer's disease.
Keller JN; Hanni KB; Markesbery WR
J Neurochem; 2000 Jul; 75(1):436-9. PubMed ID: 10854289
[TBL] [Abstract][Full Text] [Related]
19. Proteomic identification of brain proteins in the canine model of human aging following a long-term treatment with antioxidants and a program of behavioral enrichment: relevance to Alzheimer's disease.
Opii WO; Joshi G; Head E; Milgram NW; Muggenburg BA; Klein JB; Pierce WM; Cotman CW; Butterfield DA
Neurobiol Aging; 2008 Jan; 29(1):51-70. PubMed ID: 17055614
[TBL] [Abstract][Full Text] [Related]
20. Increased levels of neuronal thread protein in cerebrospinal fluid of patients with Alzheimer's disease.
de la Monte SM; Volicer L; Hauser SL; Wands JR
Ann Neurol; 1992 Dec; 32(6):733-42. PubMed ID: 1471863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
